In the midst of the Zarxio (filgrastim-sndz) biosimilar review, FDA inadvertently sent a CMC-related information request intended for the product’s sponsor, Sandoz Inc., to another entity.
More Stories About Zarxio’s Review
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?